High dose ondansetron for reducing motion sickness in highly susceptible subjects

Aviation Space and Environmental Medicine

Volumn 78, Issue 7, 2007, Pages 686-692

  Muth, Eric R ^a   Elkins, Amanda N ^a  

^a CLEMSON UNIVERSITY   (United States)

Author keywords

Anti emetics; Electrogastrography; Gastric tachyarrhythmia; Nausea

Indexed keywords

ONDANSETRON; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; ELECTROGASTROGRAPHY; FEMALE; HEAD MOVEMENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTION SICKNESS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; ROTATION; TACHYCARDIA;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIEMETICS; DIMENHYDRINATE; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL MOTILITY; HEAD MOVEMENTS; HUMANS; MALE; MOTION SICKNESS; ONDANSETRON; QUESTIONNAIRES; ROTATION;

EID: 34447269442     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Allen S, Matzkin S, Satnick R. The effects of dimenhydrinate on simulator motion sickness. Journal of Undergraduate Psychological Research 1976; 3:33-9.
2. Brandt T, Dichgans J, Wagner W. Drug effectiveness on experimental optokinetic and vestibular motion sickness. Aerosp Med 1974; 45:1291-7.
3. Caldwell J, Caldwell J. Fatigue in military aviation: an overview of U.S. military approved pharmacological countermeasures. Aerosp Med 2005; 76(7, Suppl.):C39-51.
4. DeMulder PHM, Seynaeve C, Vermorken JD, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113:834-40.
5. Fatolitits P, Muth ER, Cohn J, Stripling R. Does lag matter? An exploration into visual lag perception and its relationship to motion sickness [Abstract]. Aviat Space Environ Med 2004; 75(5, Suppl.):B111.
6. Gianaros PJ, Muth ER, Mordkoff JT, et al. A questionnaire for the assessment of the multiple dimensions of motion sickness. Aviat Space Environ Med 2001; 72:115-9.
7. Gordon CR, Gonen A, Nachum Z, et al. The effects of dimenhydrinate, cinnarizine, and transdermal scopolamine on performance. J Psychopharmacol 2001; 15:167-72.
8. Graybeil A, Lackner J. Treatment of severe motion sickness with antimotion sickness drug injections. Aviat Space Environ Med 1987; 58:773-6.
9. Graybiel A, Wood C, Knepton J, et al. Human assay of antimotion sickness drugs, Aviat Space Environ Med 1975; 46:1107-18.
10. Honkavaara P. Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. Br J Anaesth 1995; 76:316-8.
11. Hu S, Glaser KM, Hoffman TS, et al. Motion sickness susceptibility to optokinetic rotation correlates to past history of motion sickness. Aviat Space Environ Med 1996; 67:320-4.
12. Koch KL. Motion sickness. In, Sleisenger MH, ed. The handbook of nausea and vomiting. New York: The Parthenon Publishing Group; 1993:43-60.
13. Kovac A, Pearman M, Khalil S, et al. Ondansetron prevents postoperative emesis in male outpatients. J Clin Anesth 1996; 8:644-51.
14. Levine ME, Chillas JC, Stern RM, Knox GW. The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness. Aviat Space Environ Med 2000; 71:1111-4.
15. Liberman M, Howe S, Lane M. Ondansetron versus placebo for prophylaxis of nausea and vomiting in patients undergoing ambulatory laparoscopic cholecystectomy. Am J Surg 2000; 179:60-2.
16. Miller KE, Muth ER. Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat Space Environ Med 2004; 75:227-34.
17. Muth ER, Jokerst MD, Stern RM, Koch KL. Effects of dimenhydrinate on gastric tachyarrhythmia and symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995; 66:1041-5.
18. Muth ER, Stern RM, Thayer JF, Koch KL. Assessment of the multiple dimensions of nausea: the nausea profile. J Psychosom Res 1995; 40:511-20.
19. Noda K, Ikdea M, Taguchi T, et al. Clinical assessment of remosetron HCl oral preparation in the treatment of nausea and vomiting induced by cisplatin: a multicenter, randomized, parallel-design, double-blind, comparative study with ondansetron HCl. Curr Ther Res 2002; 63:636-48.
20. Pykko I, Schalen L, Jantti V, Magnusson M. A reduction of vestibule-visual integration during transdermally administered scopolamine and dimenhydrinate. Acta Otolaryngol Suppl. 1984; 406:167-73.
21. Reason JT, Brand JJ. Motion sickness. London: Academic Press; 1975:181-6.
22. Stern RM, Koch KL, Leibowitz HW, et al. Tachygastria and motion sickness. Aviat Space Environ Med 1985; 56:1074-7.
23. Stott JRR, Barnes GR, Wright RJ, Ruddock CJS. The effect on motion sickness and oculomotor function of GR38032F, a 5-HT3 receptor antagonist with anti-emetic properties. Br J Clin Pharmacol 1989; 27:147-57.
24. Wood CD, Stewart JJ, Wood MJ, Mims M. Effectiveness and duration of intramuscular antimotion sickness medications. J Clin Pharmacol 1992; 32:1008-12.